Sera Prognostics Inc
NASDAQ:SERA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sera Prognostics Inc
NASDAQ:SERA
|
US |
|
Spero Therapeutics Inc
NASDAQ:SPRO
|
US |
|
F
|
FinecoBank Banca Fineco SpA
OTC:FCBBF
|
IT |
|
A
|
Alliance Laundry Holdings Inc
NYSE:ALH
|
US |
|
N
|
NC Housing PCL
SET:NCH
|
TH |
|
Henan Hengxing Science & Technology Co Ltd
SZSE:002132
|
CN |
|
Steadfast Group Ltd
ASX:SDF
|
AU |
|
Zhejiang Fuchunjiang Environmental Thermoelectric Co Ltd
SZSE:002479
|
CN |
|
G
|
Guangdong LingXiao Pump Industry Co Ltd
SZSE:002884
|
CN |
|
L
|
LB Aluminium Bhd
KLSE:LBALUM
|
MY |
|
China Oil Hbp Science & Technology Co Ltd
SZSE:002554
|
CN |
|
Regulus Resources Inc
XTSX:REG
|
CA |
|
Uranium Energy Corp
XETRA:U6Z
|
US |
|
B
|
Bellavista Resources Ltd
ASX:BVR
|
AU |
|
ContextVision AB
OSE:CONTX
|
SE |
|
K
|
Kojamo Oyj
OMXH:KOJAMO
|
FI |
|
Adani Total Gas Ltd
NSE:ATGL
|
IN |
|
FM Mattsson AB (publ)
STO:FMM B
|
SE |
|
A
|
Arcandor AG
SWB:ARO
|
DE |
|
C
|
Chengdu KSW Technologies Co Ltd
SSE:688283
|
CN |
|
Grupo Posadas SAB de CV
BMV:POSADASA
|
MX |
|
South Bow Corp
NYSE:SOBO
|
CA |
|
Mako Gold Ltd
ASX:MKG
|
AU |
|
Sterlite Technologies Ltd
NSE:STLTECH
|
IN |
Sera Prognostics Inc
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
Sera Prognostics, Inc. engages in the provision of personalized diagnostics to predict and manage pregnancy complications. The company is headquartered in Salt Lake City, Utah and currently employs 115 full-time employees. The company went IPO on 2021-07-15. The company has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. The firm's commercial product, the PreTRM test, is a blood-based biomarker test to accurately predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 19 or 20 of gestation. Its biomarker pregnancy pipeline includes preeclampsia, molecular time-to-birth, gestational diabetes mellitus (GDM), fetal growth restriction, stillbirth and postpartum depression.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
